The Leucine Rich Repeat Containing G Protein Coupled Receptor 5 pipeline drugs market research report outlays comprehensive information on the Leucine Rich Repeat Containing G Protein Coupled Receptor 5 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Leucine Rich Repeat Containing G Protein Coupled Receptor 5 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology which include the indications Solid Tumor, and Metastatic Colorectal Cancer. It also reviews key players involved in Leucine Rich Repeat Containing G Protein Coupled Receptor 5 targeted therapeutics development with respective active and dormant or discontinued products.
The Leucine Rich Repeat Containing G Protein Coupled Receptor 5 pipeline targets constitutes close to five molecules. Out of which, approximately five molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, and Preclinical stages are 1, 1, and 3 respectively.
Leucine Rich Repeat Containing G Protein Coupled Receptor 5 overview
Leucine Rich Repeat Containing G Protein-Coupled Receptor 5, abbreviated as LGR5, is a cell surface receptor belonging to the G protein-coupled receptor (GPCR) superfamily. LGR5 is recognized for its critical role in regulating stem cell functions and tissue homeostasis in various organs. The receptor is characterized by the presence of leucine-rich repeats in its extracellular domain, contributing to its ability to interact with specific ligands. LGR5 is widely expressed in various tissues, with notable prominence in stem cell populations. The receptor’s significance lies in its involvement in the Wnt signaling pathway, a crucial molecular pathway implicated in cell proliferation, differentiation, and tissue regeneration. In the absence of Wnt signaling, LGR5 is targeted for ubiquitin-mediated degradation. However, upon activation of the Wnt pathway, LGR5 is stabilized, allowing it to contribute to the regulation of stem cell maintenance and self-renewal. One of the well-studied roles of LGR5 is its association with intestinal stem cells, where it marks a subpopulation of actively dividing, multipotent cells crucial for maintaining the integrity of the intestinal epithelium. Additionally, LGR5 has been implicated in other tissues, such as the hair follicles, liver, and stomach, where it plays a role in tissue regeneration and repair.
For a complete picture of Leucine Rich Repeat Containing G Protein Coupled Receptor 5’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
